This study aimed to determine GPC3 expression rate in HCC patients. Materials and methods: A retrospective cross-sectional study based on 132 cases of hepatocellular carcinoma at Cho Ray Hospital. Surgically resected tissues from 132 HCC were collected and stained for GPC3 by immunohistochemistry. Results: Glypican-3 was expressed in 92/132 hepatocellular carcinoma patients (69,7%). GPC3 expression was more frequently observed in poorly differentiated HCC, higher AFP levels ≥ 400ng/ml than GPC3-negative patients, the difference in the frequency being statistically significant. Conclusions: Glypican-3 expression was highly prevalent in hepatocellular carcinoma patients and more frequent in hepatocellular carcinoma with in poorly differentiated hepatocellular carcinoma, higher AFP levels.